+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Oncology Based In-Vivo CRO Market - Global Forecast 2026-2032- Product Image
Oncology Based In-Vivo CRO Market - Global Forecast 2026-2032- Product Image
Sale

Oncology Based In-Vivo CRO Market - Global Forecast 2026-2032

  • Report

  • 185 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 5888779
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Oncology Based In-Vivo CRO Market is projected to reach USD 1.65 Billion in 2026. It is expected to continue growing at a CAGR of 8.41%, reaching USD 2.69 Billion by 2032.

Oncology-Based In-Vivo CROs Support Translational Cancer Research

Oncology-based in-vivo contract research organizations (CROs) provide outsourced animal-model research used to evaluate cancer biology, therapeutic activity, pharmacology, toxicology, and biomarker relationships. Their work supports decisions before clinical testing, while requiring rigorous study design, animal-welfare oversight, reproducibility, and alignment with applicable regulatory expectations. Demand is shaped by the complexity of oncology pipelines and the need for specialized models, validated endpoints, and integrated data interpretation.

Model Complexity and Translational Rigor Are Reshaping Outsourced Research

The landscape is shifting from routine efficacy testing toward more translationally relevant study programs. Sponsors increasingly require orthotopic, patient-derived, genetically engineered, humanized, and immune-competent models where scientifically justified. Multiparametric readouts, longitudinal monitoring, pharmacokinetic and pharmacodynamic integration, and biomarker evaluation are becoming central to study value. At the same time, sponsors and regulators continue to emphasize the principles of replacement, reduction, and refinement, increasing the importance of study quality and appropriate model selection.

Artificial Intelligence Strengthens Study Design, Interpretation, and Operational Control

Artificial intelligence can improve oncology in-vivo research by helping teams prioritize models, identify treatment-response patterns, segment imaging data, and integrate pathology, molecular, and pharmacology results. Machine-learning tools may also support protocol optimization, anomaly detection, and earlier recognition of data-quality issues. However, these benefits depend on well-annotated datasets, transparent validation, controlled data pipelines, and expert review. AI does not remove the need for biological judgment, ethical oversight, or confirmation in appropriately designed experiments.

Regional Conditions Create Distinct Operating Priorities Across Six Markets

North America combines deep biomedical research infrastructure with established regulatory and institutional animal-care frameworks. Europe places strong emphasis on welfare, documentation, and alternatives to animal use, while the European research environment supports advanced translational models. Asia-Pacific offers expanding oncology research capacity, specialized technical expertise, and varied regulatory environments. Latin America is developing its outsourced research capabilities, with access, infrastructure, and regulatory harmonization remaining important considerations. The Middle East is building life-science capacity in selected hubs and may rely on international partnerships for complex studies. Africa presents emerging opportunities alongside uneven access to specialized facilities, trained personnel, and advanced model systems.

International Groups Influence Standards, Access, and Research Collaboration

ASEAN economies are strengthening biomedical capabilities at different speeds, making local compliance knowledge and cross-border coordination important. BRICS members span substantial scientific and manufacturing resources but differ in infrastructure, regulatory practice, and access to validated oncology models. The European Union supports harmonized principles while retaining national implementation requirements. G7 countries generally contribute advanced research, regulatory, and technology ecosystems. GCC states are investing in health and life-science infrastructure, often through international collaboration. NATO members represent a broad research network in which data governance, biosafety, procurement, and institutional standards can vary across jurisdictions.

Country-Level Capabilities Differ in Models, Regulation, and Translational Integration

The United States and Canada offer mature oncology research ecosystems and broad access to specialized CRO services. The United Kingdom, Germany, France, Italy, and Spain combine established academic and pharmaceutical research with European welfare and compliance requirements. Japan and South Korea provide advanced biomedical capabilities and strong technical expertise. China has extensive research infrastructure and a large scientific workforce, with regulatory and institutional requirements requiring careful local assessment. India is expanding its preclinical and biotechnology capacity. Australia maintains rigorous research governance and specialized capabilities. Brazil and Mexico have important regional roles, while Russia’s research environment requires close attention to applicable legal, operational, and collaboration constraints.

Leaders Should Prioritize Scientific Fit, Compliance, and Data Transparency

Industry leaders should select CRO partners by demonstrated expertise in the required tumor type, model, endpoint, and therapeutic modality rather than by capacity alone. Protocols should define translational objectives, randomization, blinding where feasible, statistical assumptions, humane endpoints, and data-integrity controls before study initiation. Sponsors should evaluate facility accreditation, veterinary oversight, personnel training, biosafety procedures, sample custody, and audit readiness. Integrated pharmacology, pathology, imaging, and biomarker plans can improve interpretability. AI should be introduced through validated use cases with documented performance, human review, cybersecurity safeguards, and version control. Multi-region programs should include early regulatory mapping and clear ownership of data, samples, and intellectual property.

Methodology Combines Structured Evidence Review With Scientific Validation

This executive summary is based on a qualitative assessment of the oncology-based in-vivo CRO domain, organized around service scope, translational requirements, model innovation, technology adoption, regulatory considerations, and geographic research conditions. Insights are derived from established scientific and operational principles rather than undisclosed market estimates or projections. Regional, group, and country comparisons consider research infrastructure, oncology activity, compliance environments, workforce capability, and collaboration patterns. Findings should be interpreted as strategic context and validated against current local regulations, institutional policies, and study-specific scientific requirements.

Specialized, Ethical, and Data-Driven Execution Defines Competitive Readiness

Oncology-based in-vivo CROs remain important to translational research because they connect therapeutic concepts with evidence on efficacy, mechanism, safety, and biomarkers before clinical development. The strongest operating models will combine scientifically appropriate animal systems, disciplined welfare practices, reproducible execution, integrated analytics, and transparent reporting. Regional and country differences make regulatory and operational diligence essential, while responsible AI adoption can improve efficiency without substituting for expert interpretation. Sponsors that align partner selection and study design with these principles will be better positioned to generate credible, decision-ready evidence.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Oncology Based In-Vivo CRO Market, by Model Type
7.1. Introduction
7.2. Human Tumor Models
7.2.1. CDX
7.2.2. PDX
7.3. Animal Tumor Models
7.3.1. Rodent
7.3.2. Canine
7.3.3. Rabbit
7.3.4. Zebrafish
8. Oncology Based In-Vivo CRO Market, by Route Of Administration
8.1. Introduction
8.2. Intravenous
8.3. Oral
8.4. Subcutaneous
9. Oncology Based In-Vivo CRO Market, by Cancer Indication
9.1. Introduction
9.2. Solid Tumors
9.2.1. Breast Cancer
9.2.2. Lung Cancer
9.2.3. Colorectal Cancer
9.2.4. Pancreatic Cancer
9.2.5. Liver Cancer
9.3. Hematological Cancers
9.3.1. Leukemia
9.3.2. Lymphoma
9.3.3. Multiple Myeloma
9.4. Rare Cancers
9.4.1. Sarcoma
9.4.2. Neuroendocrine Tumors
9.4.3. Pediatric Cancers
10. Oncology Based In-Vivo CRO Market, by Study Duration
10.1. Introduction
10.2. Short-Term Studies
10.3. Long-Term Studies
11. Oncology Based In-Vivo CRO Market, by Therapy
11.1. Introduction
11.2. Chemotherapy
11.3. Immunotherapy
11.3.1. Checkpoint Inhibitors
11.3.2. Cytokine Therapies
11.3.3. Cancer Vaccines
11.4. Targeted Therapy
11.4.1. Kinase Inhibitors
11.4.2. Small Molecule Inhibitors
11.5. Biologics
11.5.1. Monoclonal Antibodies
11.5.2. Antibody-Drug Conjugates (ADCs)
11.6. Cell & Gene Therapies
11.6.1. CAR-T Cell Models
11.6.2. TCR-Engineered Cell Models
11.7. Nanotherapeutics
11.7.1. Polymer-Based Nanoparticles
11.7.2. Liposomal Formulations
12. Oncology Based In-Vivo CRO Market, by End User
12.1. Introduction
12.2. Academia & Research Institute
12.3. Pharmaceutical & Biotechnology Companies
12.4. Government & Public Research Organizations
13. Oncology Based In-Vivo CRO Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. Europe
13.4. North America
13.5. Latin America
13.6. Africa
13.7. Middle East
14. Oncology Based In-Vivo CRO Market, by Group
14.1. Introduction
14.2. NATO
14.3. G7
14.4. BRICS
14.5. European Union
14.6. ASEAN
14.7. GCC
15. Oncology Based In-Vivo CRO Market, by Country
15.1. Introduction
15.2. China
15.3. United States
15.4. Japan
15.5. India
15.6. Germany
15.7. United Kingdom
15.8. Australia
15.9. France
15.10. South Korea
15.11. Canada
15.12. Italy
15.13. Brazil
15.14. Mexico
15.15. Russia
15.16. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Charles River Laboratories International, Inc.
17.2. WuXi AppTec Co., Ltd.
17.3. Laboratory Corporation of America Holdings
17.4. ICON plc
17.5. Parexel International Corporation
17.6. Eurofins Scientific S.E.
17.7. Medpace, Inc.
17.8. Pharmaron Beijing Co., Ltd.
17.9. Champions Oncology, Inc
17.10. Syngene International Limited
17.11. Evotec SE
17.12. Crown Bioscience, Inc.
17.13. Novotech Health Holdings
17.14. Aragen Life Sciences Ltd.
17.15. The Jackson Laboratory
17.16. Linical Co., Ltd.
17.17. Experimental Pharmacology & Oncology Berlin-Buch GmbH
17.18. Aurigene Pharmaceutical Services Ltd.
17.19. Noble Life Sciences
17.20. Taconic Biosciences, Inc.
17.21. Melior Discovery Inc.
17.22. Reaction Biology Corporation
17.23. Altogen Labs
17.24. Cellvax, SAS
17.25. Explicyte
17.26. Imavita S.A.S.
17.27. InnoSer
17.28. IVRS AB
17.29. Oncodesign Services
17.30. Pharmatest Services
17.31. The Living Tumor Laboratory
17.32. TheraIndx Lifesciences Pvt. Ltd.
18. Key Experts
LIST OF FIGURES
FIGURE 1. Global Oncology Based In-Vivo CRO Market, Years Considered for the Study
FIGURE 2. Global Oncology Based In-Vivo CRO Market, Research Design
FIGURE 3. Global Oncology Based In-Vivo CRO Market, Research Framework
FIGURE 4. Global Oncology Based In-Vivo CRO Market, Data Triangulation
FIGURE 5. Global Oncology Based In-Vivo CRO Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Oncology Based In-Vivo CRO Market Size, by Model Type, 2025 vs 2032 (%)
FIGURE 7. Global Oncology Based In-Vivo CRO Market Size, by Model Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Oncology Based In-Vivo CRO Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 9. Global Oncology Based In-Vivo CRO Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Oncology Based In-Vivo CRO Market Size, by Cancer Indication, 2025 vs 2032 (%)
FIGURE 11. Global Oncology Based In-Vivo CRO Market Size, by Cancer Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Oncology Based In-Vivo CRO Market Size, by Study Duration, 2025 vs 2032 (%)
FIGURE 13. Global Oncology Based In-Vivo CRO Market Size, by Study Duration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Oncology Based In-Vivo CRO Market Size, by Therapy, 2025 vs 2032 (%)
FIGURE 15. Global Oncology Based In-Vivo CRO Market Size, by Therapy, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Oncology Based In-Vivo CRO Market Size, by End User, 2025 vs 2032 (%)
FIGURE 17. Global Oncology Based In-Vivo CRO Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Oncology Based In-Vivo CRO Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global Oncology Based In-Vivo CRO Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Oncology Based In-Vivo CRO Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Oncology Based In-Vivo CRO Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global Oncology Based In-Vivo CRO Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Oncology Based In-Vivo CRO Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Oncology Based In-Vivo CRO Market Segmentation & Coverage
TABLE 2. Global Oncology Based In-Vivo CRO Market Size, 2017-2032 (USD Million)
TABLE 3. Global Oncology Based In-Vivo CRO Market Size, by Model Type, 2017-2032 (USD Million)
TABLE 4. Global Human Tumor Models Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Human Tumor Models Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Human Tumor Models Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global CDX Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global CDX Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global CDX Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global PDX Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global PDX Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global PDX Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Animal Tumor Models Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Animal Tumor Models Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Animal Tumor Models Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Rodent Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Rodent Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Rodent Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Canine Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Canine Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Canine Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Rabbit Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Rabbit Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Rabbit Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Zebrafish Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Zebrafish Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Zebrafish Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Oncology Based In-Vivo CRO Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 29. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Oncology Based In-Vivo CRO Market Size, by Cancer Indication, 2017-2032 (USD Million)
TABLE 39. Global Solid Tumors Market Size, by Region, 2017-2032 (USD Million)
TABLE 40. Global Solid Tumors Market Size, by Group, 2017-2032 (USD Million)
TABLE 41. Global Solid Tumors Market Size, by Country, 2017-2032 (USD Million)
TABLE 42. Global Breast Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 43. Global Breast Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 44. Global Breast Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 45. Global Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Lung Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Colorectal Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Colorectal Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Colorectal Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Pancreatic Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Pancreatic Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Pancreatic Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Liver Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Liver Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Liver Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Hematological Cancers Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Hematological Cancers Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Hematological Cancers Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global Leukemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Global Leukemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 62. Global Leukemia Market Size, by Country, 2017-2032 (USD Million)
TABLE 63. Global Lymphoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Global Lymphoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 65. Global Lymphoma Market Size, by Country, 2017-2032 (USD Million)
TABLE 66. Global Multiple Myeloma Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Global Multiple Myeloma Market Size, by Group, 2017-2032 (USD Million)
TABLE 68. Global Multiple Myeloma Market Size, by Country, 2017-2032 (USD Million)
TABLE 69. Global Rare Cancers Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Global Rare Cancers Market Size, by Group, 2017-2032 (USD Million)
TABLE 71. Global Rare Cancers Market Size, by Country, 2017-2032 (USD Million)
TABLE 72. Global Sarcoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Global Sarcoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 74. Global Sarcoma Market Size, by Country, 2017-2032 (USD Million)
TABLE 75. Global Neuroendocrine Tumors Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Global Neuroendocrine Tumors Market Size, by Group, 2017-2032 (USD Million)
TABLE 77. Global Neuroendocrine Tumors Market Size, by Country, 2017-2032 (USD Million)
TABLE 78. Global Pediatric Cancers Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Global Pediatric Cancers Market Size, by Group, 2017-2032 (USD Million)
TABLE 80. Global Pediatric Cancers Market Size, by Country, 2017-2032 (USD Million)
TABLE 81. Global Oncology Based In-Vivo CRO Market Size, by Study Duration, 2017-2032 (USD Million)
TABLE 82. Global Short-Term Studies Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Global Short-Term Studies Market Size, by Group, 2017-2032 (USD Million)
TABLE 84. Global Short-Term Studies Market Size, by Country, 2017-2032 (USD Million)
TABLE 85. Global Long-Term Studies Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Global Long-Term Studies Market Size, by Group, 2017-2032 (USD Million)
TABLE 87. Global Long-Term Studies Market Size, by Country, 2017-2032 (USD Million)
TABLE 88. Global Oncology Based In-Vivo CRO Market Size, by Therapy, 2017-2032 (USD Million)
TABLE 89. Global Chemotherapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Global Chemotherapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 91. Global Chemotherapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 92. Global Immunotherapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 93. Global Immunotherapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 94. Global Immunotherapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 95. Global Checkpoint Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 96. Global Checkpoint Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 97. Global Checkpoint Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 98. Global Cytokine Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 99. Global Cytokine Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 100. Global Cytokine Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 101. Global Cancer Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 102. Global Cancer Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 103. Global Cancer Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 104. Global Targeted Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 105. Global Targeted Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 106. Global Targeted Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 107. Global Kinase Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 108. Global Kinase Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 109. Global Kinase Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 110. Global Small Molecule Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 111. Global Small Molecule Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 112. Global Small Molecule Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 113. Global Biologics Market Size, by Region, 2017-2032 (USD Million)
TABLE 114. Global Biologics Market Size, by Group, 2017-2032 (USD Million)
TABLE 115. Global Biologics Market Size, by Country, 2017-2032 (USD Million)
TABLE 116. Global Monoclonal Antibodies Market Size, by Region, 2017-2032 (USD Million)
TABLE 117. Global Monoclonal Antibodies Market Size, by Group, 2017-2032 (USD Million)
TABLE 118. Global Monoclonal Antibodies Market Size, by Country, 2017-2032 (USD Million)
TABLE 119. Global Antibody-Drug Conjugates (ADCs) Market Size, by Region, 2017-2032 (USD Million)
TABLE 120. Global Antibody-Drug Conjugates (ADCs) Market Size, by Group, 2017-2032 (USD Million)
TABLE 121. Global Antibody-Drug Conjugates (ADCs) Market Size, by Country, 2017-2032 (USD Million)
TABLE 122. Global Cell & Gene Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 123. Global Cell & Gene Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 124. Global Cell & Gene Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 125. Global CAR-T Cell Models Market Size, by Region, 2017-2032 (USD Million)
TABLE 126. Global CAR-T Cell Models Market Size, by Group, 2017-2032 (USD Million)
TABLE 127. Global CAR-T Cell Models Market Size, by Country, 2017-2032 (USD Million)
TABLE 128. Global TCR-Engineered Cell Models Market Size, by Region, 2017-2032 (USD Million)
TABLE 129. Global TCR-Engineered Cell Models Market Size, by Group, 2017-2032 (USD Million)
TABLE 130. Global TCR-Engineered Cell Models Market Size, by Country, 2017-2032 (USD Million)
TABLE 131. Global Nanotherapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 132. Global Nanotherapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 133. Global Nanotherapeutics Market Size, by Country, 2017-2032 (USD Million)
TABLE 134. Global Polymer-Based Nanoparticles Market Size, by Region, 2017-2032 (USD Million)
TABLE 135. Global Polymer-Based Nanoparticles Market Size, by Group, 2017-2032 (USD Million)
TABLE 136. Global Polymer-Based Nanoparticles Market Size, by Country, 2017-2032 (USD Million)
TABLE 137. Global Liposomal Formulations Market Size, by Region, 2017-2032 (USD Million)
TABLE 138. Global Liposomal Formulations Market Size, by Group, 2017-2032 (USD Million)
TABLE 139. Global Liposomal Formulations Market Size, by Country, 2017-2032 (USD Million)
TABLE 140. Global Oncology Based In-Vivo CRO Market Size, by End User, 2017-2032 (USD Million)
TABLE 141. Global Academia & Research Institute Market Size, by Region, 2017-2032 (USD Million)
TABLE 142. Global Academia & Research Institute Market Size, by Group, 2017-2032 (USD Million)
TABLE 143. Global Academia & Research Institute Market Size, by Country, 2017-2032 (USD Million)
TABLE 144. Global Pharmaceutical & Biotechnology Companies Market Size, by Region, 2017-2032 (USD Million)
TABLE 145. Global Pharmaceutical & Biotechnology Companies Market Size, by Group, 2017-2032 (USD Million)
TABLE 146. Global Pharmaceutical & Biotechnology Companies Market Size, by Country, 2017-2032 (USD Million)
TABLE 147. Global Government & Public Research Organizations Market Size, by Region, 2017-2032 (USD Million)
TABLE 148. Global Government & Public Research Organizations Market Size, by Group, 2017-2032 (USD Million)
TABLE 149. Global Government & Public Research Organizations Market Size, by Country, 2017-2032 (USD Million)
TABLE 150. Global Oncology Based In-Vivo CRO Market Size, by Region, 2017-2032 (USD Million)
TABLE 151. Asia-Pacific Oncology Based In-Vivo CRO Market Size, by Region, 2017-2032 (USD Million)
TABLE 152. Asia-Pacific Oncology Based In-Vivo CRO Market Size, by Model Type, 2017-2032 (USD Million)
TABLE 153. Asia-Pacific Oncology Based In-Vivo CRO Market Size, by Human Tumor Models, 2017-2032 (USD Million)
TABLE 154. Asia-Pacific Oncology Based In-Vivo CRO Market Size, by Animal Tumor Models, 2017-2032 (USD Million)
TABLE 155. Asia-Pacific Oncology Based In-Vivo CRO Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 156. Asia-Pacific Oncology Based In-Vivo CRO Market Size, by Cancer Indication, 2017-2032 (USD Million)
TABLE 157. Asia-Pacific Oncology Based In-Vivo CRO Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 158. Asia-Pacific Oncology Based In-Vivo CRO Market Size, by Hematological Cancers, 2017-2032 (USD Million)
TABLE 159. Asia-Pacific Oncology Based In-Vivo CRO Market Size, by Rare Cancers, 2017-2032 (USD Million)
TABLE 160. Asia-Pacific Oncology Based In-Vivo CRO Market Size, by Study Duration, 2017-2032 (USD Million)
TABLE 161. Asia-Pacific Oncology Based In-Vivo CRO Market Size, by Therapy, 2017-2032 (USD Million)
TABLE 162. Asia-Pacific Oncology Based In-Vivo CRO Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 163. Asia-Pacific Oncology Based In-Vivo CRO Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 164. Asia-Pacific Oncology Based In-Vivo CRO Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 165. Asia-Pacific Oncology Based In-Vivo CRO Market Size, by Cell & Gene Therapies, 2017-2032 (USD Million)
TABLE 166. Asia-Pacific Oncology Based In-Vivo CRO Market Size, by Nanotherapeutics, 2017-2032 (USD Million)
TABLE 167. Asia-Pacific Oncology Based In-Vivo CRO Market Size, by End User, 2017-2032 (USD Million)
TABLE 168. Europe Oncology Based In-Vivo CRO Market Size, by Region, 2017-2032 (USD Million)
TABLE 169. Europe Oncology Based In-Vivo CRO Market Size, by Model Type, 2017-2032 (USD Million)
TABLE 170. Europe Oncology Based In-Vivo CRO Market Size, by Human Tumor Models, 2017-2032 (USD Million)
TABLE 171. Europe Oncology Based In-Vivo CRO Market Size, by Animal Tumor Models, 2017-2032 (USD Million)
TABLE 172. Europe Oncology Based In-Vivo CRO Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 173. Europe Oncology Based In-Vivo CRO Market Size, by Cancer Indication, 2017-2032 (USD Million)
TABLE 174. Europe Oncology Based In-Vivo CRO Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 175. Europe Oncology Based In-Vivo CRO Market Size, by Hematological Cancers, 2017-2032 (USD Million)
TABLE 176. Europe Oncology Based In-Vivo CRO Market Size, by Rare Cancers, 2017-2032 (USD Million)
TABLE 177. Europe Oncology Based In-Vivo CRO Market Size, by Study Duration, 2017-2032 (USD Million)
TABLE 178. Europe Oncology Based In-Vivo CRO Market Size, by Therapy, 2017-2032 (USD Million)
TABLE 179. Europe Oncology Based In-Vivo CRO Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 180. Europe Oncology Based In-Vivo CRO Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 181. Europe Oncology Based In-Vivo CRO Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 182. Europe Oncology Based In-Vivo CRO Market Size, by Cell & Gene Therapies, 2017-2032 (USD Million)
TABLE 183. Europe Oncology Based In-Vivo CRO Market Size, by Nanotherapeutics, 2017-2032 (USD Million)
TABLE 184. Europe Oncology Based In-Vivo CRO Market Size, by End User, 2017-2032 (USD Million)
TABLE 185. North America Oncology Based In-Vivo CRO Market Size, by Region, 2017-2032 (USD Million)
TABLE 186. North America Oncology Based In-Vivo CRO Market Size, by Model Type, 2017-2032 (USD Million)
TABLE 187. North America Oncology Based In-Vivo CRO Market Size, by Human Tumor Models, 2017-2032 (USD Million)
TABLE 188. North America Oncology Based In-Vivo CRO Market Size, by Animal Tumor Models, 2017-2032 (USD Million)
TABLE 189. North America Oncology Based In-Vivo CRO Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 190. North America Oncology Based In-Vivo CRO Market Size, by Cancer Indication, 2017-2032 (USD Million)
TABLE 191. North America Oncology Based In-Vivo CRO Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 192. North America Oncology Based In-Vivo CRO Market Size, by Hematological Cancers, 2017-2032 (USD Million)
TABLE 193. North America Oncology Based In-Vivo CRO Market Size, by Rare Cancers, 2017-2032 (USD Million)
TABLE 194. North America Oncology Based In-Vivo CRO Market Size, by Study Duration, 2017-2032 (USD Million)
TABLE 195. North America Oncology Based In-Vivo CRO Market Size, by Therapy, 2017-2032 (USD Million)
TABLE 196. North America Oncology Based In-Vivo CRO Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 197. North America Oncology Based In-Vivo CRO Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 198. North America Oncology Based In-Vivo CRO Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 199. North America Oncology Based In-Vivo CRO Market Size, by Cell & Gene Therapies, 2017-2032 (USD Million)
TABLE 200. North America Oncology Based In-Vivo CRO Market Size, by Nanotherapeutics, 2017-2032 (USD Million)
TABLE 201. North America Oncology Based In-Vivo CRO Market Size, by End User, 2017-2032 (USD Million)
TABLE 202. Latin America Oncology Based In-Vivo CRO Market Size, by Region, 2017-2032 (USD Million)
TABLE 203. Latin America Oncology Based In-Vivo CRO Market Size, by Model Type, 2017-2032 (USD Million)
TABLE 204. Latin America Oncology Based In-Vivo CRO Market Size, by Human Tumor Models, 2017-2032 (USD Million)
TABLE 205. Latin America Oncology Based In-Vivo CRO Market Size, by Animal Tumor Models, 2017-2032 (USD Million)
TABLE 206. Latin America Oncology Based In-Vivo CRO Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 207. Latin America Oncology Based In-Vivo CRO Market Size, by Cancer Indication, 2017-2032 (USD Million)
TABLE 208. Latin America Oncology Based In-Vivo CRO Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 209. Latin America Oncology Based In-Vivo CRO Market Size, by Hematological Cancers, 2017-2032 (USD Million)
TABLE 210. Latin America Oncology Based In-Vivo CRO Market Size, by Rare Cancers, 2017-2032 (USD Million)
TABLE 211. Latin America Oncology Based In-Vivo CRO Market Size, by Study Duration, 2017-2032 (USD Million)
TABLE 212. Latin America Oncology Based In-Vivo CRO Market Size, by Therapy, 2017-2032 (USD Million)
TABLE 213. Latin America Oncology Based In-Vivo CRO Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 214. Latin America Oncology Based In-Vivo CRO Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 215. Latin America Oncology Based In-Vivo CRO Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 216. Latin America Oncology Based In-Vivo CRO Market Size, by Cell & Gene Therapies, 2017-2032 (USD Million)
TABLE 217. Latin America Oncology Based In-Vivo CRO Market Size, by Nanotherapeutics, 2017-2032 (USD Million)
TABLE 218. Latin America Oncology Based In-Vivo CRO Market Size, by End User, 2017-2032 (USD Million)
TABLE 219. Africa Oncology Based In-Vivo CRO Market Size, by Region, 2017-2032 (USD Million)
TABLE 220. Africa Oncology Based In-Vivo CRO Market Size, by Model Type, 2017-2032 (USD Million)
TABLE 221. Africa Oncology Based In-Vivo CRO Market Size, by Human Tumor Models, 2017-2032 (USD Million)
TABLE 222. Africa Oncology Based In-Vivo CRO Market Size, by Animal Tumor Models, 2017-2032 (USD Million)
TABLE 223. Africa Oncology Based In-Vivo CRO Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 224. Africa Oncology Based In-Vivo CRO Market Size, by Cancer Indication, 2017-2032 (USD Million)
TABLE 225. Africa Oncology Based In-Vivo CRO Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 226. Africa Oncology Based In-Vivo CRO Market Size, by Hematological Cancers, 2017-2032 (USD Million)
TABLE 227. Africa Oncology Based In-Vivo CRO Market Size, by Rare Cancers, 2017-2032 (USD Million)
TABLE 228. Africa Oncology Based In-Vivo CRO Market Size, by Study Duration, 2017-2032 (USD Million)
TABLE 229. Africa Oncology Based In-Vivo CRO Market Size, by Therapy, 2017-2032 (USD Million)
TABLE 230. Africa Oncology Based In-Vivo CRO Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 231. Africa Oncology Based In-Vivo CRO Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 232. Africa Oncology Based In-Vivo CRO Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 233. Africa Oncology Based In-Vivo CRO Market Size, by Cell & Gene Therapies, 2017-2032 (USD Million)
TABLE 234. Africa Oncology Based In-Vivo CRO Market Size, by Nanotherapeutics, 2017-2032 (USD Million)
TABLE 235. Africa Oncology Based In-Vivo CRO Market Size, by End User, 2017-2032 (USD Million)
TABLE 236. Middle East Oncology Based In-Vivo CRO Market Size, by Region, 2017-2032 (USD Million)
TABLE 237. Middle East Oncology Based In-Vivo CRO Market Size, by Model Type, 2017-2032 (USD Million)
TABLE 238. Middle East Oncology Based In-Vivo CRO Market Size, by Human Tumor Models, 2017-2032 (USD Million)
TABLE 239. Middle East Oncology Based In-Vivo CRO Market Size, by Animal Tumor Models, 2017-2032 (USD Million)
TABLE 240. Middle East Oncology Based In-Vivo CRO Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 241. Middle East Oncology Based In-Vivo CRO Market Size, by Cancer Indication, 2017-2032 (USD Million)
TABLE 242. Middle East Oncology Based In-Vivo CRO Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 243. Middle East Oncology Based In-Vivo CRO Market Size, by Hematological Cancers, 2017-2032 (USD Million)
TABLE 244. Middle East Oncology Based In-Vivo CRO Market Size, by Rare Cancers, 2017-2032 (USD Million)
TABLE 245. Middle East Oncology Based In-Vivo CRO Market Size, by Study Duration, 2017-2032 (USD Million)
TABLE 246. Middle East Oncology Based In-Vivo CRO Market Size, by Therapy, 2017-2032 (USD Million)
TABLE 247. Middle East Oncology Based In-Vivo CRO Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 248. Middle East Oncology Based In-Vivo CRO Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 249. Middle East Oncology Based In-Vivo CRO Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 250. Middle East Oncology Based In-Vivo CRO Market Size, by Cell & Gene Therapies, 2017-2032 (USD Million)
TABLE 251. Middle East Oncology Based In-Vivo CRO Market Size, by Nanotherapeutics, 2017-2032 (USD Million)
TABLE 252. Middle East Oncology Based In-Vivo CRO Market Size, by End User, 2017-2032 (USD Million)
TABLE 253. Global Oncology Based In-Vivo CRO Market Size, by Group, 2017-2032 (USD Million)
TABLE 254. NATO Oncology Based In-Vivo CRO Market Size, by Group, 2017-2032 (USD Million)
TABLE 255. NATO Oncology Based In-Vivo CRO Market Size, by Model Type, 2017-2032 (USD Million)
TABLE 256. NATO Oncology Based In-Vivo CRO Market Size, by Human Tumor Models, 2017-2032 (USD Million)
TABLE 257. NATO Oncology Based In-Vivo CRO Market Size, by Animal Tumor Models, 2017-2032 (USD Million)
TABLE 258. NATO Oncology Based In-Vivo CRO Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 259. NATO Oncology Based In-Vivo CRO Market Size, by Cancer Indication, 2017-2032 (USD Million)
TABLE 260. NATO Oncology Based In-Vivo CRO Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 261. NATO Oncology Based In-Vivo CRO Market Size, by Hematological Cancers, 2017-2032 (USD Million)
TABLE 262. NATO Oncology Based In-Vivo CRO Market Size, by Rare Cancers, 2017-2032 (USD Million)
TABLE 263. NATO Oncology Based In-Vivo CRO Market Size, by Study Duration, 2017-2032 (USD Million)
TABLE 264. NATO Oncology Based In-Vivo CRO Market Size, by Therapy, 2017-2032 (USD Million)
TABLE 265. NATO Oncology Based In-Vivo CRO Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 266. NATO Oncology Based In-Vivo CRO Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 267. NATO Oncology Based In-Vivo CRO Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 268. NATO Oncology Based In-Vivo CRO Market Size, by Cell & Gene Therapies, 2017-2032 (USD Million)
TABLE 269. NATO Oncology Based In-Vivo CRO Market Size, by Nanotherapeutics, 2017-2032 (USD Million)
TABLE 270. NATO Oncology Based In-Vivo CRO Market Size, by End User, 2017-2032 (USD Million)
TABLE 271. G7 Oncology Based In-Vivo CRO Market Size, by Group, 2017-2032 (USD Million)
TABLE 272. G7 Oncology Based In-Vivo CRO Market Size, by Model Type, 2017-2032 (USD Million)
TABLE 273. G7 Oncology Based In-Vivo CRO Market Size, by Human Tumor Models, 2017-2032 (USD Million)
TABLE 274. G7 Oncology Based In-Vivo CRO Market Size, by Animal Tumor Models, 2017-2032 (USD Million)
TABLE 275. G7 Oncology Based In-Vivo CRO Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 276. G7 Oncology Based In-Vivo CRO Market Size, by Cancer Indication, 2017-2032 (USD Million)
TABLE 277. G7 Oncology Based In-Vivo CRO Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 278. G7 Oncology Based In-Vivo CRO Market Size, by Hematological Cancers, 2017-2032 (USD Million)
TABLE 279. G7 Oncology Based In-Vivo CRO Market Size, by Rare Cancers, 2017-2032 (USD Million)
TABLE 280. G7 Oncology Based In-Vivo CRO Market Size, by Study Duration, 2017-2032 (USD Million)
TABLE 281. G7 Oncology Based In-Vivo CRO Market Size, by Therapy, 2017-2032 (USD Million)
TABLE 282. G7 Oncology Based In-Vivo CRO Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 283. G7 Oncology Based In-Vivo CRO Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 284. G7 Oncology Based In-Vivo CRO Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 285. G7 Oncology Based In-Vivo CRO Market Size, by Cell & Gene Therapies, 2017-2032 (USD Million)
TABLE 286. G7 Oncology Based In-Vivo CRO Market Size, by Nanotherapeutics, 2017-2032 (USD Million)
TABLE 287. G7 Oncology Based In-Vivo CRO Market Size, by End User, 2017-2032 (USD Million)
TABLE 288. BRICS Oncology Based In-Vivo CRO Market Size, by Group, 2017-2032 (USD Million)
TABLE 289. BRICS Oncology Based In-Vivo CRO Market Size, by Model Type, 2017-2032 (USD Million)
TABLE 290. BRICS Oncology Based In-Vivo CRO Market Size, by Human Tumor Models, 2017-2032 (USD Million)
TABLE 291. BRICS Oncology Based In-Vivo CRO Market Size, by Animal Tumor Models, 2017-2032 (USD Million)
TABLE 292. BRICS Oncology Based In-Vivo CRO Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 293. BRICS Oncology Based In-Vivo CRO Market Size, by Cancer Indication, 2017-2032 (USD Million)
TABLE 294. BRICS Oncology Based In-Vivo CRO Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 295. BRICS Oncology Based In-Vivo CRO Market Size, by Hematological Cancers, 2017-2032 (USD Million)
TABLE 296. BRICS Oncology Based In-Vivo CRO Market Size, by Rare Cancers, 2017-2032 (USD Million)
TABLE 297. BRICS Oncology Based In-Vivo CRO Market Size, by Study Duration, 2017-2032 (USD Million)
TABLE 298. BRICS Oncology Based In-Vivo CRO Market Size, by Therapy, 2017-2032 (USD Million)
TABLE 299. BRICS Oncology Based In-Vivo CRO Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 300. BRICS Oncology Based In-Vivo CRO Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 301. BRICS Oncology Based In-Vivo CRO Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 302. BRICS Oncology Based In-Vivo CRO Market Size, by Cell & Gene Therapies, 2017-2032 (USD Million)
TABLE 303. BRICS Oncology Based In-Vivo CRO Market Size, by Nanotherapeutics, 2017-2032 (USD Million)
TABLE 304. BRICS Oncology Based In-Vivo CRO Market Size, by End User, 2017-2032 (USD Million)
TABLE 305. European Union Oncology Based In-Vivo CRO Market Size, by Group, 2017-2032 (USD Million)
TABLE 306. European Union Oncology Based In-Vivo CRO Market Size, by Model Type, 2017-2032 (USD Million)
TABLE 307. European Union Oncology Based In-Vivo CRO Market Size, by Human Tumor Models, 2017-2032 (USD Million)
TABLE 308. European Union Oncology Based In-Vivo CRO Market Size, by Animal Tumor Models, 2017-2032 (USD Million)
TABLE 309. European Union Oncology Based In-Vivo CRO Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 310. European Union Oncology Based In-Vivo CRO Market Size, by Cancer Indication, 2017-2032 (USD Million)
TABLE 311. European Union Oncology Based In-Vivo CRO Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 312. European Union Oncology Based In-Vivo CRO Market Size, by Hematological Cancers, 2017-2032 (USD Million)
TABLE 313. European Union Oncology Based In-Vivo CRO Market Size, by Rare Cancers, 2017-2032 (USD Million)
TABLE 314. European Union Oncology Based In-Vivo CRO Market Size, by Study Duration, 2017-2032 (USD Million)
TABLE 315. European Union Oncology Based In-Vivo CRO Market Size, by Therapy, 2017-2032 (USD Million)
TABLE 316. European Union Oncology Based In-Vivo CRO Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 317. European Union Oncology Based In-Vivo CRO Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 318. European Union Oncology Based In-Vivo CRO Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 319. European Union Oncology Based In-Vivo CRO Market Size, by Cell & Gene Therapies, 2017-2032 (USD Million)
TABLE 320. European Union Oncology Based In-Vivo CRO Market Size, by Nanotherapeutics, 2017-2032 (USD Million)
TABLE 321. European Union Oncology Based In-Vivo CRO Market Size, by End User, 2017-2032 (USD Million)
TABLE 322. ASEAN Oncology Based In-Vivo CRO Market Size, by Group, 2017-2032 (USD Million)
TABLE 323. ASEAN Oncology Based In-Vivo CRO Market Size, by Model Type, 2017-2032 (USD Million)
TABLE 324. ASEAN Oncology Based In-Vivo CRO Market Size, by Human Tumor Models, 2017-2032 (USD Million)
TABLE 325. ASEAN Oncology Based In-Vivo CRO Market Size, by Animal Tumor Models, 2017-2032 (USD Million)
TABLE 326. ASEAN Oncology Based In-Vivo CRO Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 327. ASEAN Oncology Based In-Vivo CRO Market Size, by Cancer Indication, 2017-2032 (USD Million)
TABLE 328. ASEAN Oncology Based In-Vivo CRO Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 329. ASEAN Oncology Based In-Vivo CRO Market Size, by Hematological Cancers, 2017-2032 (USD Million)
TABLE 330. ASEAN Oncology Based In-Vivo CRO Market Size, by Rare Cancers, 2017-2032 (USD Million)
TABLE 331. ASEAN Oncology Based In-Vivo CRO Market Size, by Study Duration, 2017-2032 (USD Million)
TABLE 332. ASEAN Oncology Based In-Vivo CRO Market Size, by Therapy, 2017-2032 (USD Million)
TABLE 333. ASEAN Oncology Based In-Vivo CRO Market Size, by Immunotherapy, 2017-2032 (USD Million)
TABLE 334. ASEAN Oncology Based In-Vivo CRO Market Size, by Targeted Therapy, 2017-2032 (USD Million)
TABLE 335. ASEAN Oncology Based In-Vivo CRO Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 336. ASEAN Oncology Based In-Vivo CRO Market Size, by Cell & Gene Therapies, 2017-2032 (USD Million)
TABLE 337. ASEAN Oncology Based In-Vivo CRO Market Size, by Nanotherapeutics, 2017-2032 (USD Million)
TABLE 338. ASEAN Oncology Based In-Vivo CRO Market Size, by End User, 2017-2032 (USD Million)
TABLE 339. GCC Oncology Based In-Vivo CRO Market Size, by Group, 2017-2032 (USD Million)
TABLE 340. GCC Oncology Based In-Vivo CRO Market Size, by Model Type, 2017-2032 (USD Million)
TABLE 341. GCC Oncology Based In-Vivo CRO Market Size, by Human Tumor Models, 2017-2032 (USD Million)
TABLE 342. GCC Oncology Based In-Vivo CRO Market Size, by Animal Tumor Models, 2017-2032 (USD Million)
TABLE 343. GCC Oncology Based In-Vivo CRO Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 344. GCC Oncology Based In-Vivo CRO Market Size, by Cancer Indication, 2017-2032 (USD Million)
TABLE 345. GCC Oncology Based In-Vivo CRO Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 346. GCC Oncology Based In-Vivo CRO Market Size, by Hematological Cancers, 2017-2032 (USD Million)
TABLE 347. GCC Oncology Based In-Vivo CRO Market

Companies Mentioned

  • Charles River Laboratories International, Inc.
  • WuXi AppTec Co., Ltd.
  • Laboratory Corporation of America Holdings
  • ICON plc
  • Parexel International Corporation
  • Eurofins Scientific S.E.
  • Medpace, Inc.
  • Pharmaron Beijing Co., Ltd.
  • Champions Oncology, Inc
  • Syngene International Limited
  • Evotec SE
  • Crown Bioscience, Inc.
  • Novotech Health Holdings
  • Aragen Life Sciences Ltd.
  • The Jackson Laboratory
  • Linical Co., Ltd.
  • Experimental Pharmacology & Oncology Berlin-Buch GmbH
  • Aurigene Pharmaceutical Services Ltd.
  • Noble Life Sciences
  • Taconic Biosciences, Inc.
  • Melior Discovery Inc.
  • Reaction Biology Corporation
  • Altogen Labs
  • Cellvax, SAS
  • Explicyte
  • Imavita S.A.S.
  • InnoSer
  • IVRS AB
  • Oncodesign Services
  • Pharmatest Services
  • The Living Tumor Laboratory
  • TheraIndx Lifesciences Pvt. Ltd.

Related Topics

Related Reports

In Vivo CRO Market - Global Forecast 2026-2032 - Product Image

In Vivo CRO Market - Global Forecast 2026-2032

  • Report
  • 183 Pages
  • Global
From
Oncology Based In-Vivo CRO - Global Strategic Business Report - Product Image

Oncology Based In-Vivo CRO - Global Strategic Business Report

  • Report
  • 129 Pages
  • Global
From
Oncology Based In-Vivo CRO Market Report by Indication, Model, Application, and Region 2026-2034 - Product Image

Oncology Based In-Vivo CRO Market Report by Indication, Model, Application, and Region 2026-2034

  • Report
  • 136 Pages
  • Global
From
Oncology Based in-Vivo CRO Market Report 2026 - Product Image

Oncology Based in-Vivo CRO Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Oncology Based in-Vivo CRO Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends (2026-2035) - Product Image

Oncology Based in-Vivo CRO Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends (2026-2035)

  • Report
  • 350 Pages
  • Global
From

About the Oncology Based In Vivo CRO Market

The Oncology Based In Vivo CRO market is a subset of the biotechnology industry that focuses on providing preclinical services for oncology drug development. These services include animal models, pharmacology, toxicology, and imaging studies. The goal of these services is to provide data that can be used to support the safety and efficacy of oncology drugs. The market is driven by the increasing demand for new treatments for cancer, as well as the need for more efficient and cost-effective drug development. The Oncology Based In Vivo CRO market is highly competitive, with a number of companies offering services in this area. Some of the major players in the market include Charles River Laboratories, Covance, WIL Research, and Envigo. Other companies in the market include MPI Research, SRI International, and Taconic Biosciences. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.